Eli Lilly (LLY) concluded the recent trading session at $796.03, signifying a -0.44% move from its prior day's close.

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

A national medical firm has announced it will launch a $3 billion expansion of its Kenosha County facility and will bring 750 ...

Fox News senor medical analyst Dr. Marc Siegel weighs in on the FDA weighing a crackdown on food dye, major food companies ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

Lilly’s investment and the UK government’s strategic support for life sciences and healthcare represent a pivotal moment for the industry.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

An experimental drug stops advanced breast cancer from progressing in some people with tumors that have grown resistant to ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

Shares of Hims & Hers Health Inc. slid to a three-week low on Wednesday before recovering some losses, even as retail sentiment remained ‘bullish’ despite concerns surrounding a major announcement by ...

In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of ...